ArticleBMC oral health2026
The potential role of silver nanoparticles in the tongue wound healing.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe tongue is a complex muscular organ that can be affected by chronic ulcers and malignant tumors, which need proper management to improve healing and tissue regeneration. Hence, we aimed to assess the efficiency of adipose tissue stem cells (ADSCs) treated with/without silver nanoparticles (AgNPs) on tongue wound healing. MATERIALS AND
methodsFifty-six male white albino rats were divided into four groups; group I: tongue defects were prepared on the tongue dorsal surfaces using a tissue punch rotary drill for standardization, and were left untreated, group II: tongue defects were treated subepithelial using 2.5 µg/ml AgNPs solution using insulin syringe on the same day of defect preparation, group III: tongue defects were injected with 200 µl of ADSCs suspension (3.5 × 105 cells) and group IV: tongue defects were injected with 200 µl of ADSCs previously treated with 2.5 µg/ml AgNPs solution. Four- and seven-day follow-up following treatment, tongue specimens were collected, and histological assessment was conducted by hematoxylin and eosin (H&E) stain and immunohistochemical assessment of anti-TNF-alpha and anti-TGF-β, followed by histomorphometric assessment. Two-way ANOVA was utilized to compare between the groups after 4 and 7 days.
resultsThe treated groups revealed a significant improvement characterized histologically by regenerated tissue with well-developed, thick-walled, and well-organized vessels and a significant decrease in defect depth in comparison with the control group. Group IV displayed a significant reduction in TNF-alpha and a significant increase in TGF-β antibodies, denoting its anti-inflammatory and neovascularization actions correspondingly.
conclusionADSCs treated with AgNPs could significantly enhance regeneration and filling of tongue defects by decreasing tissue inflammation and improving neovascularization, being better than using ADSCs or AgNPs alone. Therefore, it may be a possible treatment plan for enhancing the healing of tongue ulcers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.